Current Atherosclerosis Reports

, Volume 2, Issue 4, pp 314–320

Diet and pharmacologic therapy of obesity to modify atherosclerosis

  • Peter H. Jones


More than half of the men and women in the United States are overweight or obese. Obesity is associated with an increased risk for various diseases, most notably, hypertension, diabetes mellitus, dyslipidemia, and coronary heart disease (CHD). The location of excessive body fat, particularly in the visceral area, has the strongest association with these factors that comprise the insulin resistance syndrome. A reduction in as little as 10% of baseline weight has been shown to improve the control of blood pressure and glucose, as well as to reduce triglycerides and increase high-density lipoprotein (HDL) cholesterol. Therefore, obesity should be considered a predisposing CHD risk factor, and treatment with diet, exercise, and newer pharmacologic agents can help patients achieve and maintain desired weight-loss goals.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Mokdad AH, Serdula MK, et al.: The spread of the obesity epidemic in the United States, 1991–1998. JAMA 1999, 282:1519–1523.PubMedCrossRefGoogle Scholar
  2. 2.
    Must A, Spadano J, Cookley EH, et al.: The disease burden associated with overweight and obesity. JAMA 1999, 282:1523–1529.PubMedCrossRefGoogle Scholar
  3. 3.
    Flegal MD, Carroll RJ, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: prevalence and trends. Int J Obes Relat Metab Disord 1998, 22:39–47.PubMedCrossRefGoogle Scholar
  4. 4.
    National Institute of Health Consensus Development Conference Statement: Health implications of obesity. Ann Intern Med 1985, 103:147–151.Google Scholar
  5. 5.
    Van Itallie TB: Health implications of overweight and obesity in the United States. Ann Intern Med 1985, 103:983–988.PubMedGoogle Scholar
  6. 6.
    National Institute of Health: The National Heart, Lung and Blood Institute: Clinical guidelines in the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998, 6:51S-209S.Google Scholar
  7. 7.
    Eckel RH, Krauss RM for the AHA Nutrition Committee: American Heart Association call to action: obesity as a major risk factor for coronary heart disease: Circulation 1998, 97:2099–2100.PubMedGoogle Scholar
  8. 8.
    Hubert HB, Feinleib M, McNamara PM, Castelli WP: Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983, 67:968–977.PubMedGoogle Scholar
  9. 9.
    Kannel WB, Cupples LA, Ramaswami R, et al.: Regional obesity and risk of cardiovascular disease: the Framingham Study. J Clin Epidemiol 1991, 44:183–190.PubMedCrossRefGoogle Scholar
  10. 10.
    Willett WC, Manson JE, Stampfer MJ, et al.: Weight, weight change and coronary heart disease in women: risk within the “normal” weight range. JAMA 1995, 273:461–465.PubMedCrossRefGoogle Scholar
  11. 11.
    Rexrode KM, Carey VJ, Hennekens CH, et al.: Abdominal obesity and coronary heart disease in women. JAMA 1995, 273:462–465.Google Scholar
  12. 12.
    Rexrode KM, Hennekens CH, Willett WC, et al.: A prospective study of body mass index weight change and risk of stroke in women. JAMA 1997, 277:1539–1545.PubMedCrossRefGoogle Scholar
  13. 13.
    Donahue RP, Abbott RD, Bloom E, et al.: Central obesity and coronary heart disease in men. Lancet 1987, 821–824.Google Scholar
  14. 14.
    Rimm EB, Stampfer MJ, Giovannucci E, et al.: Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995, 141:1117–1127.PubMedGoogle Scholar
  15. 15.
    Rabkin SW, Mathewson FA, Hsu PH: Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26-year observation period: the Manitoba Study. Am J Cardiol 1977, 39:452.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee CD, Blair SN, Jackson AS: Cardiorespiratory fitness, body composition, and all-cause cardiovascular disease mortality in men. Am J Clin Nutr 1999, 69:373–380.PubMedGoogle Scholar
  17. 17.
    Stern MP, Haffner SM: Body fat distribution and hyperinsulnemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 1986, 6:123–130.PubMedGoogle Scholar
  18. 18.
    Stern MP: Do nonisulin dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996, 124:110–116.PubMedGoogle Scholar
  19. 19.
    Hotamisligil GS, Shargill NS, Spieglman BM: Adipose expression of tumor necrosis factor alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87–91.PubMedCrossRefGoogle Scholar
  20. 20.
    Fried SK, Bunkin DA, Greenberg AS: Omental and subcutaneous adipose tissues of obeses subjects release interleukin-6. J Clin Endocrinol Metab 1998, 83:847–850.PubMedCrossRefGoogle Scholar
  21. 21.
    Arita Y, Kihara S, Ouchi N, et al.: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.PubMedGoogle Scholar
  23. 23.
    Thompson D, Edelsberg J, Colditz GA, et al.: Lifetime health and economic consequences of obesity. Arch Intern Med 1999, 159:2177–2183.PubMedCrossRefGoogle Scholar
  24. 24.
    Colditz GA, Wilbett WC, Rotnitzky A, Manson JE: Weight gain as a risk factor for clinical diabetes in women. Am Intern Med 1995, 122:481–486.Google Scholar
  25. 25.
    Cassano PA, Rosner B, Vokonas PS, Weiss ST: Obesity and body fat distribution in relation to the incidence of noninsulin dependent diabetes mellitus: a prospective cohort study of men in the Normative Aging Study. Am J Epidemiol 1992, 136:1474–1486.PubMedGoogle Scholar
  26. 26.
    Manson JE, Stampfer MJ, Hennekens CH, Willett WC: Body weight and longevity: a reassement. JAMA 1987, 257:353–358.PubMedCrossRefGoogle Scholar
  27. 27.
    Lee J-M, Manson JE, Hennekens CH, Paffenbarger RS: Body weight and mortality: a 27-year follow-up of middle-aged men. JAMA 1993, 270:2823–2828.PubMedCrossRefGoogle Scholar
  28. 28.
    Lew EA, Garfinkel L: Variations in mortality by weight among 750,000 men and women. J Chron Dis 1979, 32:563–576.PubMedCrossRefGoogle Scholar
  29. 29.
    Williamson DF, Pamuk E, Thun M, et al.: Prospective study of intentional weight loss and mortality in never-smoking overweight US women aged 40–64 years. Am J Epidemiol 1995, 141:1128–1141.PubMedGoogle Scholar
  30. 30.
    Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obesity 1992, 16:397–414.Google Scholar
  31. 31.
    The Treatment of Mild Hypertension Research Group: The Treatment of Mild Hypertension Study:a randomized, placebo-controlled trial of a nutritional-hygenic regimen along with various drug mono-therapies. Arch Intern Med 1991, 151:143–1423.Google Scholar
  32. 32.
    Reisin E, Abel R, Modan M, et al.: Effect of weight loss without salt restriction on the reduction of blood pressure in overweight hypertensive patients. N Engl J Med 1978, 298:1–6.PubMedCrossRefGoogle Scholar
  33. 33.
    The Sixth Request of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.Arch Intern Med 1997, 2413–2446.Google Scholar
  34. 34.
    American Diabetes Association: Clinical practice recommendations 1999. Diabetes Care 1999, 22 (Suppl 1):S1–114.Google Scholar
  35. 35.
    Henry RR, Wiest-Kent TA, Scheaffer L, et al.: Metabolic consequences of very-low-calorie diet therapy in obese noninsulin dependent diabetic and nondiabetic subjects. Diabetes 1986, 35:155–164.PubMedCrossRefGoogle Scholar
  36. 36.
    Wing RR, Marcus MD, Salata R, et al.: Effects of a very-low-calorie diet on long term glycemic control in obese Type-II diabetic subjects. Arch Intern Med 1991, 151:1334–1340.PubMedCrossRefGoogle Scholar
  37. 37.
    Kirschner MA, Schneider G, Ertel NH, Gorman J: An 8-year experience with a very low calorie formula diet for control of major obesity. Int J Obesity 1988, 69–80.Google Scholar
  38. 38.
    Sjostrom CD, Lissner L, Wedel H, Sjostrom L: Reduction in incidence of diabetes, hypertension, and lipid disturbances offer intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obesity Research 1999, 7:477–484.PubMedGoogle Scholar
  39. 39.
    National Cholesterol Education Program: Second report of the Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994, 94:1329–1445.Google Scholar
  40. 40.
    Dattilo AM, Kris-Etherton PM: Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56:320–328.PubMedGoogle Scholar
  41. 41.
    Noakes M, Clifton PM: Weight loss and plasma lipids. Curr Opin Lipidol 2000, 11:65–70.PubMedCrossRefGoogle Scholar
  42. 42.
    Miettinen TA, Puska P, Gylling H, et al.: Reduction of serm cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995, 333:1308–1312.PubMedCrossRefGoogle Scholar
  43. 43.
    Bullor DL, Keesey RE: A meta-analysis of the factors affecting exercise-induced changes in body mass, fat mass, and fat-free mass in males and females. Int J Obesity 1991, 15:717–726.Google Scholar
  44. 44.
    Pavlou KN, Krey S, Steffee WP: Exercise as an adjunct to weight loss and maintenance in moderately obese subjects. Am J Clin Nutr 1989, 49:1115–1123.PubMedGoogle Scholar
  45. 45.
    Atkinson RL: Use of drugs in the treatment of obesity. Annu Rev Nutr 1997, 17:383.PubMedCrossRefGoogle Scholar
  46. 46.
    Bremer JM, Scott RS, Lintott CJ: Dexfenfluramine reduces cardiovascular risk factors. Int J Obesity 1994, 18:199–205.Google Scholar
  47. 47.
    Marks SJ, Moore NR, Clark ML, et al.: Reduction in visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDIM. Obesity Res 1996, 4:1–7.Google Scholar
  48. 48.
    Holdaway M, Wallace E, Westbrooke L, Gamble G: Effect of dexfenfluramine on body weight, blood pressure, insulin resistance, and serum cholesterol in obese individuals. Int J Obesity 1995, 19:749–751.Google Scholar
  49. 49.
    Swinburn BA, Carmichael HE, Wilson MR: Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. Int J Obesity 1996, 20:1235–1240.Google Scholar
  50. 50.
    Kolanowski J, Younis LT, Yanbutsele R, Detry J-M: Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenegic activity in obese hypertensive patients. Eur J Clin Pharmacol 1992, 42:599–606.PubMedCrossRefGoogle Scholar
  51. 51.
    Connolly HM, Crary JL, McGoon MD, et al.: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997, 37:551–558.Google Scholar
  52. 52.
    Bray GA, Ryan DH, Gordon D, et al.: A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996, 4:263.PubMedGoogle Scholar
  53. 53.
    Davidson MH, Hauptman J, DiGirolamo et al.: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999, 281:235–242.PubMedCrossRefGoogle Scholar
  54. 54.
    Sjostrom L, Rissanen A, Andersen T, et al.: Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998, 352:167–172.PubMedCrossRefGoogle Scholar
  55. 55.
    Hollander PA, Elbein SC, Hirsch IB, et al.: Role of Orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized, double-blind study. Diabetes Care 1998, 21:1288–1294.PubMedCrossRefGoogle Scholar
  56. 56.
    Hill JO, Hauphan J, Anderson JW, et al.: Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999, 69:1108–1116.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Peter H. Jones
    • 1
  1. 1.Department of Medicine, Section of Atherosclerosis and Lipid ResearchBaylor College of MedicineHoustonUSA

Personalised recommendations